[Translation] A multicenter, randomized, open-label phase III clinical study to evaluate the efficacy, safety, and pharmacokinetics of leuprorelin emulsion injection in the treatment of premenopausal breast cancer

以给药后第4周至48周血清E2浓度维持在绝经后水平（≤ 30 pg/mL）的抑制率为有效性评价的替代性指标，评估亮丙瑞林注射乳剂给药后治疗绝经前乳腺癌的疗效。

[Translation]

The efficacy of leuprorelin emulsion injection in the treatment of premenopausal breast cancer was evaluated using the inhibition rate of serum E2 concentration maintained at postmenopausal levels (≤ 30 pg/mL) from the 4th to 48th week after administration as a surrogate indicator for efficacy evaluation.

Start Date21 Aug 2024

Sponsor / Collaborator

FAREVA PAU

[+2]

NCT06449027

/ Not yet recruitingPhase 3

A Phase III, Multicenter, Randomized, Open-Label Study to Assess the Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

The study is to assess the safety, efficacy and pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Start Date01 Jun 2024

Sponsor / Collaborator

Changchun Genescience Pharmaceuticals Co., Ltd.

NCT05493709

/ RecruitingPhase 3

An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 Mg Controlled Release in Patients with Central (Gonadotropin-Dependent) Precocious Puberty (Casppian Study)

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.

Start Date02 Jun 2023

Sponsor / Collaborator

Foresee Pharmaceuticals Co., Ltd.

[+2]

100 Clinical Results associated with Leuprolide Mesylate

100 Translational Medicine associated with Leuprolide Mesylate

100 Patents (Medical) associated with Leuprolide Mesylate

1,173

Literatures (Medical) associated with Leuprolide Mesylate

01 Feb 2025·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Enhancing leuprolide penetration through enterocytes via the ER-Golgi pathway using lipophilic complexation

Article

Author: Jiang, Xuling ; Meng, Jia ; Peng, Cheng ; Qian, Feng ; Chan, May Yee

Oral delivery of peptide drugs remains one of the most formidable challenges in the frontier of pharmaceutical research. Peptide drugs typically suffer from exceptionally low oral bioavailability, primarily attributed to rigorous enzymatic degradation within the gastrointestinal (GI) tract, limited ability to traverse the enterocyte barrier, and significant first-pass hepatic metabolism. Absorption of peptide drugs via the lymphatic route could potentially bypass intracellular lysosome degradation and hepatic first-pass metabolism. In this study, we present a strategy to enhance the lymphatic absorption of the model peptide leuprolide (LEU) by diverting its intracellular trafficking towards the endoplasmic-reticulum (ER)-Golgi pathway. Complexes were formed between LEU and lipophilic excipient and then formulated as an oral emulsion. We observed that the penetration of LEU in the emulsion across the Caco-2 cell monolayer model was diverted from the endosome-lysosome pathway, and LEU entered the bloodstream via the mesenteric lymph nodes (MLNs). The data obtained illustrates that the lipophilic LEU complexes could improve enterocyte permeability and bypass lysosomal degradation, and the change of absorption pathway may reduce hepatic first pass metabolism.

01 Jan 2025·EUROPEAN UROLOGY

Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Article

Author: Tombal, Bertrand ; Bossi, Alberto ; Shore, Neal ; Brown, Bruce ; Collins, Sean ; Hunsche, Elke ; Morgans, Alicia K. ; Zhu, Emily

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated testosterone suppression to castrate levels in men with advanced prostate cancer (PCa) in the HERO study.Since advanced PCa and its treatments can impact patients' daily life, it is imperative to understand the impact of systemic therapy on patient health-related quality of life (HRQOL).To report the HRQOL for patients on relugolix compared with those on leuprolide in on-treatment and testosterone recovery periods of the HERO study.A phase 3 randomized controlled study was conducted in 934 patients with advanced PCa.Patients underwent 2:1 randomization and received relugolix 120 mg orally once daily or leuprolide 3-mo injections for 48 wk.Testosterone recovery was evaluated in a patient subset.HRQOL evaluations were based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) and the Prostate Cancer Module (EORTC QLQ-PR25) during treatment and testosterone recovery phases.In a post hoc anal., predictors of HRQOL deterioration were evaluated.No statistically significant differences between the two groups were found in changes from baseline to the end of treatment in either the EORTC QLQ-C30 or the EORTC QLQ-PR25 instrument.During the testosterone recovery phase, hormonal treatment-related symptoms scores were lower for relugolix than for leuprolide, suggesting a lower burden of hormone-related symptoms associated with a treatment that has more rapid testosterone recovery after treatment cessation.Limitations include low patient numbers in the testosterone recovery group.Oral relugolix is a therapeutic option with similar patient-reported HRQOL to leuprolide, providing an oral option for androgen deprivation therapy associated with a more rapid testosterone reductionIn men with advanced prostate cancer, relugolix had similar health-related quality of life to leuprolide.

01 Jan 2025·UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Testosterone recovery after androgen deprivation therapy

Article

Author: Neill, Clayton ; Bennett, Richard ; Ho, Austin Y ; Li, Yutai ; Suk-Ouichai, Chalairat ; Ross, Ashley E ; Morgans, Alicia K. ; Kumar, Sai Kaushik Shankar Ramesh ; Li, Eric V. ; Ross, Ashley E. ; Patel, Hiten D. ; Ho, Austin Y. ; Schaeffer, Edward M. ; Schaeffer, Edward M ; Morgans, Alicia K ; Li, Eric V ; Suk-ouichai, Chalairat ; Patel, Hiten D

PURPOSE:

Finite courses of androgen deprivation therapy (ADT) are often utilized in men undergoing treatment for prostate cancer. Previous evidence suggests that timing of testosterone (T) recovery can be variable after ADT. Recently, an oral gonadotropin releasing-hormone (GnRH) antagonist, relugolix, has demonstrated more rapid T recovery than injectable GnRH agonists such as leuprolide. In this study, we sought to evaluate patient characteristics associated with T recovery in patients undergoing ADT of defined duration.

MATERIALS AND METHODS:

The Northwestern Enterprise Data Warehouse was queried for men with prostate cancer who completed a course of ADT and subsequently had a testosterone lab performed. Testosterone recovery was evaluated for levels that reached above castrate (T > 50 ng/dl), partial recovery (T > 150 ng/dl), and full recovery (T ≥ 300 ng/dl).

RESULTS:

388 men who received finite courses of ADT were identified (348 receiving leuprolide, 36 receiving relugolix, and 4 receiving degarelix). In multivariable Cox regression analysis, men who were prescribed GnRH antagonists (HR = 3.74, CI = 2.53-5.53, P ≤ 0.001) and who were younger (HR for 1 year increase in age = 0.96, CI = 0.95-0.98, P < 0.001) were more likely to achieve partial recovery. In a subgroup analysis, men who received extended ADT courses (>12 months) with a GnRH agonist had lower rates of partial T recovery (HR = 0.58, CI = 0.41-0.81, P = 0.001).

CONCLUSION:

T recovery after ADT is variable with roughly one sixth of men remaining castrate. GnRH antagonist use and younger age are associated with higher rates of T recovery after ADT. Longer ADT courses were associated with worse T recovery rates.

News (Medical) associated with Leuprolide Mesylate

13 Jan 2025

·www.prnewswire.com

Foresee Pharmaceuticals Announces the PDUFA Goal Date for the 3-month Version of CAMCEVI is August 29, 2025

TAIPEI, Jan. 13, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that the U.S. Food and Drug Administration (FDA) issued a Day-74 letter. The Day-74 letter states that the PDUFA goal date for a decision on marketing approval for the 3-month version of CAMCEVI (leuprolide mesylate 21 mg, 3-month long-acting injectable (LAI) formulation) for the treatment of adult patients with advanced prostate cancer is August 29, 2025. "This marks another important regulatory milestone for the CAMCEVI franchise," said Dr. Ben Chien, Founder and Chairman of Foresee. "With the PDUFA goal date now set, we look forward to working with the FDA through the regulatory process to bring this treatment option closer to potential regulatory approval, followed by the successful commercial launch of CAMCEVI 21 mg in near future, providing patients and the medical community with a 3-month CAMCEVI LAI in addition to CAMCEVI 42 mg 6-month LAI, currently on the market. Foresee will have a complete, differentiated ready-to-use franchise." The NDA submission for the 3-month version of CAMCEVI is supported by a previously communicated successful Phase 3 clinical study with a total of 144 advanced prostate carcinoma patients enrolled, in which treatment with leuprolide mesylate injection every 3 months was demonstrated to be effective, safe and well tolerated, with 97.9% of the subjects achieving the primary efficacy endpoint. About Foresee Pharmaceuticals Co., Ltd. Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg or the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. in April 2022. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted, while the EU regulatory submission for the 3-month version of CAMCEVI is still under preparation. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study, is ongoing. CAMCEVI 6-month LAI formulation is also being developed in a Phase 3 clinical trial in premenopausal breast cancer in China in collaboration with its partner. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, for which a Phase 1 study in healthy volunteers has been successfully completed, with development targeted in severe asthma, COPD and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is ongoing, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the first quarter of 2025. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space. SOURCE Foresee Pharmaceuticals Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3NDAPhase 2Drug Approval

04 Dec 2024

·www.prnewswire.com

Foresee Pharmaceuticals Announces Completion of US$42.1 Million Financing

TAIPEI, Dec. 4, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that it has successfully completed an underwritten public offering of 18,000,000 shares of its common stock to the public at a price of NT$76 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,368 million (or US$42.1 million at FX=32.5). The proceeds of the public offering will be used for general corporate purposes, including FP-014 (triptorelin), a ready-to-use long-acting injectable, administered either every three months or six months, in two Phase 3 clinical trials for advanced prostate cancer, respectively; FP-020 (linvemastat), an MMP-12 inhibitor, in two Phase 2 studies for both asthma and inflammatory bowel disease (IBD), and FP-045 (mirivadelgat), an ALDH2 activator, in a Phase 2 clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD). "We are pleased to announce the successful completion of the public offering. I would like to express my gratitude once again for shareholders' full support and trust in us." said Dr. Ben Chien, Founder and Chairman of Foresee. "This funding will enable us to accelerate our R&D progress and create more value for our shareholders." About Foresee Pharmaceuticals Co., Ltd. Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI® 42 mg or the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. in April 2022. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted, while the EU regulatory submission for the 3-month version of CAMCEVI is still under preparation. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study, is ongoing. Another indication of CAMCEVI 6-month LAI formulation, premenopausal breast cancer, the Phase 3 clinical trial in China is ongoing as well. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, for which a Phase 1 study in healthy volunteers has been successfully completed, with development targeted in severe asthma, COPD and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is ongoing, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the first quarter of 2025. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space. SOURCE Foresee Pharmaceuticals Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 3Clinical ResultPhase 1Drug Approval

04 Dec 2024

·endpts.com

AstraZeneca's new EVP of international amid China investigation; Janux’s $300M offering

Plus, news about Arrakis, Eli Lilly, Everest Medicines, Teva, Rondo Therapeutics, Trevi Therapeutics, Foresee Pharmaceuticals and Revolution Medicines: AstraZeneca taps new leader to run China business: The drugmaker named Iskra Reic as EVP of international, putting her in charge of its China business after Leon Wang was placed on leave while under investigation there. Wang was EVP of international and president of China. Reic, who launched the company’s vaccines and immune therapies unit, has been with AstraZeneca since 2001. — Jaimy Lee Janux’s $300M offering: The biotech is raising money after its stock soared on Tuesday thanks to early prostate cancer data . It’s been reported as a takeover target in the past. — Kyle LaHucik Arrakis shares first look at preclinical myotonic dystrophy type 1 data: Earlier this year, the RNA-targeted small molecule biotech helmed by industry veteran Michael Gilman shifted its focus from a lead cancer program to DM1, Endpoints News reported in March. “While there have been serendipitous discoveries of small molecule drugs that bind to RNA, we believe this is one of the clearest examples of a rationally designed small molecule that has been purpose-built to address an RNA disease target,” Gilman said in a Wednesday release. — Kyle LaHucik Lilly joins hot T cell engager space: The pharma giant, mostly in the news for its obesity medicines, has inked a cancer deal. It’s paying an undisclosed amount to California startup Rondo Therapeutics for a CD28-co-stimulatory bispecific antibody for an undisclosed cancer target. Multiple large pharmas have done T cell engager deals in recent months. — Kyle LaHucik Everest Medicines details early data for BTK inhibitor: In the ongoing Phase 1b/2a trial in China for patients with primary membranous nephropathy, 9 out of 11 (81.8%) patients taking the lowest dose achieved overall clinical remission after 36 weeks, and 10 out of 11 (91%) achieved immunological complete remission. In patients on the highest dose, 6 out of 7 (85.7%) patients achieved overall clinical remission. — Katherine Lewin Teva’s Ajovy bests placebo in pediatric migraine trial: Over 12 weeks, Ajovy “significantly” reduced monthly migraine days and monthly headache days compared to placebo in patients between six and 17 years old. The full data are set to be presented at the European Headache Congress in the Netherlands this week. — Katherine Lewin Trevi’s topline data for chronic cough drug: The human abuse potential study , which enrolled patients who are recreational drug users, showed a statistically significant lower “drug liking” for two doses of Trevi’s nalbuphine compared to butorphanol, a narcotic for pain with a high risk for addiction. But its stock $TRVI was down about 4% on Wednesday morning. — Katherine Lewin Foresee’s $42M raise: The Taipei and US biotech, which markets the prostate cancer drug Camcevi, secured the money by selling 18 million shares. — Kyle LaHucik Revolution Medicines upsized its public offering to $750 million, up from the $600 million it initially planned to raise . — Jaimy Lee

Clinical ResultImmunotherapy

100 Deals associated with Leuprolide Mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L02AE02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Prostate Carcinoma	IL	Foresee Pharmaceuticals Co., Ltd.	11 Jul 2024
Hormone-dependent prostate cancer	EU	Accord Healthcare SLU	24 May 2022
Hormone-dependent prostate cancer	IS	Accord Healthcare SLU	24 May 2022
Hormone-dependent prostate cancer	LI	Accord Healthcare SLU	24 May 2022
Hormone-dependent prostate cancer	NO	Accord Healthcare SLU	24 May 2022
Prostatic Cancer	US	Accord BioPharma, Inc.	25 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Premenopausal breast cancer	Phase 3	CN	FAREVA PAU	21 Aug 2024
Premenopausal breast cancer	Phase 3	CN	Changchun Genescience Pharmaceuticals Co., Ltd.	21 Aug 2024
Premenopausal breast cancer	Phase 3	CN	Foresee Pharmaceuticals Co., Ltd.	21 Aug 2024
Puberty, Precocious	Phase 3	US	Foresee Pharmaceuticals Co., Ltd.	02 Jun 2023
Puberty, Precocious	Phase 3	US	Changchun Genescience Pharmaceuticals Co., Ltd.	02 Jun 2023
Puberty, Precocious	Phase 3	CN	Foresee Pharmaceuticals Co., Ltd.	02 Jun 2023
Puberty, Precocious	Phase 3	CN	Changchun Genescience Pharmaceuticals Co., Ltd.	02 Jun 2023
Puberty, Precocious	Phase 3	PR	Foresee Pharmaceuticals Co., Ltd.	02 Jun 2023
Puberty, Precocious	Phase 3	PR	Changchun Genescience Pharmaceuticals Co., Ltd.	02 Jun 2023
Puberty, Precocious	Phase 3	TW	Changchun Genescience Pharmaceuticals Co., Ltd.	02 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02807363 (CTgov)	Phase 2	Endometriosis	35	Leuprolide (Leuprolide Oral Tablet, 4 mg QD (Treatment A))	eucfntrceq(usiznrkaad) = apkdpjetbe mykwirhski (vgxdvetofp, qriqnxzeut - usfmsclimi) View more	-	11 Feb 2022
NCT02807363 (CTgov)	Phase 2	Endometriosis	35	Leuprolide (Leuprolide Oral Tablet, 4 mg BID (Treatment B))	eucfntrceq(usiznrkaad) = tisghgshii mykwirhski (vgxdvetofp, qmlykihfqk - huhsvbajjs) View more	-	11 Feb 2022
NCT02508636 (CTgov)	Phase 2	Prostatic Cancer \| Sarcoidosis	11	Enzalutamide+Leuprolide	rpeuyzrxss(wvncgeiiwa) = ineljtjovo htzwjcfuyg (xshggjhsft, ibspuxslpz - shxafxzsra) View more	-	12 Oct 2021
NCT03261999 (CTgov)	Phase 3	Prostatic Cancer	144	Leuprolide Mesylate	pgcghnikyq(pphzrqvsaz) = glucbkwsit ngabcsdsbe (bcpwkyupmf, ppkgzxbplh - bdmhlyacof) View more	-	04 May 2020
NCT02508636 (ASCO_GU2020)	Phase 2	Prostatic Cancer	16	Leuprolide and Enzalutamide	eknxzbuhjg(iflxmgpqlo) = uenllxqnyj isbuxljzdy (lelwjymxtu, 3.47 - 4.87)	-	19 Feb 2020
NCT00123110 (CTgov)	Phase 2	Insulin Resistance	35	Metformin (Metformin)	fbhmrgzhxv(ynnzonhgtc) = jwzjouglcw oasfhovhas (maroagcsla, arupfxsdvc - rugzdqhxca) View more	-	23 May 2019
NCT00123110 (CTgov)	Phase 2	Insulin Resistance	35	Leuprolide (Leuprolide)	fbhmrgzhxv(ynnzonhgtc) = dagdofmpdf oasfhovhas (maroagcsla, wvyeoroglp - pplxsswjhn) View more	-	23 May 2019
NCT02712320 (CTgov)	Phase 3	Advanced Prostate Carcinoma	30	LMIS 50 mg	mvaubluhxk(fmzpqpkfnc) = ysscthlviw dnovllgnsk (adsmrxetcd, cqtvuommse - gkhkimlqkv) View more	-	12 Sep 2018
NCT02234115 (CTgov)	Phase 3	Advanced Prostate Carcinoma	137	Leuprolide Mesylate	lumaldbtot(jinbdcbuyb) = vxqhtibkfb jiymiuiyrn (jxncdmegil, wdjdqzwjdv - zhmznwrbfv) View more	-	13 Apr 2018
NCT01116401 (CTgov)	Phase 4	Hot Flashes \| Dyssomnias \| Depressive Disorder	29	leuprolide	xjnsaiqfyr(owsacqrdoi) = ugdspalgof fxsevsrqjo (pvsfvjgkyf, unkudkbnth - awqswcvugk) View more	-	26 Dec 2017
NCT00924469 (CTgov)	Phase 2	Localized Prostate Carcinoma	58	Prednisone+Abiraterone+Leuprolide (Abiraterone Plus Leuprolide Plus Prednisone)	npmumshwzf(oirvesxtbz) = omlzbjjobn xehezainvs (jbpckfoiqf, kqvoyeqotx - xbepcxtolf) View more	-	17 Apr 2013
NCT00924469 (CTgov)	Phase 2	Localized Prostate Carcinoma	58	Prednisone+Abiraterone+Leuprolide (Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone)	npmumshwzf(oirvesxtbz) = tagpdrwwqr xehezainvs (jbpckfoiqf, grefgozgjp - kdheixodsi) View more	-	17 Apr 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis